EURAM LIMITED

Their core work

EURAM Limited is a UK-based SME specializing in biomedical engineering for regenerative medicine applications, particularly tissue-engineered scaffolds and medical devices. They contribute manufacturing and engineering expertise to clinical research projects focused on stem cell therapies and advanced therapy medicinal products (ATMPs). Their work spans from prenatal stem cell treatments for bone disorders to tissue-engineered tracheal replacements, positioning them as a technical partner bridging device engineering and cell therapy development.

What they specialise in

How they've shifted over time

EURAM's H2020 portfolio is concentrated within a narrow window (2015–2016 project starts), making dramatic evolution difficult to trace. Their earliest project (FORECEE) was in cancer biomarker prediction — somewhat distinct from their other work. The two later projects (BOOSTB4 and TETRA) show a clear consolidation around tissue engineering, scaffold development, and stem cell-based therapies, suggesting the company sharpened its focus on regenerative medicine device support over time.

EURAM appears to be concentrating on ATMP and tissue engineering device development, making them a likely partner for future regenerative medicine projects requiring specialized manufacturing.

How they like to work

EURAM operates exclusively as a participant, never leading consortia — consistent with a specialist SME that provides focused technical capability rather than project management. With 36 unique partners across 9 countries from just 3 projects, they have joined sizeable international consortia, indicating comfort working within large, multi-disciplinary teams. Their role pattern suggests they are brought in for specific engineering or manufacturing expertise rather than driving research agendas.

Despite only 3 projects, EURAM has built connections with 36 partners across 9 countries, reflecting participation in large clinical research consortia. Their network is broadly European with no strong geographic concentration beyond their UK base.

What sets them apart

EURAM occupies a niche as a small engineering firm providing scaffold and medical device expertise to academic-led regenerative medicine consortia. Unlike university partners who focus on biological research, EURAM brings practical device manufacturing and engineering capabilities — the translation layer between lab science and clinical-grade products. For consortium builders, they offer the rare combination of SME agility with hands-on experience in ATMP regulatory pathways.

Highlights from their portfolio

• TETRA
  Focused on building a fully tissue-engineered autologous trachea — a highly ambitious clinical application combining stem cells, scaffolds, and surgical implantation.
• BOOSTB4
  Pioneering prenatal stem cell therapy for osteogenesis imperfecta (brittle bone disease), addressing an unmet clinical need with no existing treatment.